NephroGenex is an innovator in the development of drugs to treat kidney disease, with a first indication in diabetic nephropathy. We have been pioneering the development of PYRIDORIN® (pyridoxamine dihydrochloride), a late stage compound to treat the
Our clinical and regulatory teams have positioned the Phase 3 PIONEER program for success by securing from the FDA a Fast Track designation and Special Protocol Assessment (SPA) for a new endpoint that will reduce the time, cost and risk of the trial. The SPA also allows for a patient population where Pyridorin previously demonstrated a greater than 50% treatment effect in Phase 2 studies. We believe Pyridorin represents real hope for the 6 million patients with diabetic nephropathy in the U.S. alone who today have no adequate treatments available to them.